Please login to the form below

Not currently logged in
Email:
Password:

CureVac appoints chief financial officer

Pierre Kemula joins the mRNA company’s management board

CureVac Pierre KemulaTübingen, Germany-based mRNA firm CureVac has appointed Pierre Kemula as its new chief financial officer.

Kemula will have responsibility for managing CureVac's financial and capital markets activities and joins the company's management board.

Previously, Kemula served as chief financial officer of Pixium Vision, a medical technology company specialising in the development of technologies for patients with outer retinal degeneration.

He also brings experience from Ipsen, where he was vice president of corporate finance, treasury and financial markets, and from consulting firms Roland Berger, Kea & Partners, Gemini Consulting and KPMG.

Ingmar Hoerr, co-founder and chief executive officer of CureVac, said: "Adding an executive with Pierre's financial and transactional expertise, as well as his global markets experience, is a key accomplishment for CureVac as the company prepares for multiple near-term corporate and clinical milestones that have the potential to significantly contribute to its leadership position in the field of mRNA."

14th October 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...